Amine and ether compounds which modulate the CB2 receptor

1. A compound of the formula (III)

wherein for the formula (III)

is chosen independently from members of column A in Table I, and

is chosen independently from members of column B in Table I:

TABLE I

A

B

wherein X in each case is halogen or CH 3 optionally halogenated;

or a pharmaceutically acceptable salt thereof.

2. A compound chosen from

N-(5-tert-Butyl-isoxazol-3-yl)-2-(4-methoxy-phenylamino)-2-methyl-propionamide

N-(5-tert-Butyl-isoxazol-3-yl)-2-isopropylamino-2-methyl-propionamide

2-sec-Butylamino-N-(5-tert-butyl-isoxazol-3-yl)-2-methyl-propionamide

N-(5-tert-Butyl-isoxazol-3-yl)-2-(isopropyl-methyl-amino)-2-methyl-propionamide

N-(5-tert-Butyl-isoxazol-3-yl)-2-morpholin-4-yl-isobutyramide

N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexylamino-2-methyl-propionamide

2-Butylamino-N-(5-tert-butyl-isoxazol-3-yl)-2-methyl-propionamide

N-(5-tert-Butyl-isoxazol-3-yl)-2-(3-methyl-piperidin-1-yl)-isobutyramide

N-(5-tert-Butyl-isoxazol-3-yl)-2-(2-methyl-pyrrolidin-1-yl)-isobutyramide

N-(5-tert-Butyl-isoxazol-3-yl)-2-(4-methyl-piperidin-1-yl)-isobutyramide

N-(5-tert-Butyl-isoxazol-3-yl)-2-thiomorpholin-4-yl-isobutyramide

N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclopropylamino-2-methyl-propionamide

N-(5-tert-Butyl-isoxazol-3-yl)-2-(2-methyl-piperidin-1-yl)-isobutyramide

N-(5-tert-Butyl-isoxazol-3-yl)-2-(4-methoxy-piperidin-1-yl)-isobutyramide

N-(5-tert-Butyl-isoxazol-3-yl)-2-piperidin-1-yl-isobutyramide

N-(5-tert-Butyl-isoxazol-3-yl)-2-pyrrolidin-1-yl-isobutyramide

N-(5-tert-Butyl-isoxazol-3-yl)-2-(4,4-difluoro-piperidin-1-yl)-isobutyramide

2-Cyclohexylamino-2-methyl-N-(5-trifluoromethyl-pyridin-2-yl)-propionamide

2-Piperidin-1-yl-N-(5-trifluoromethyl-pyridin-2-yl)-isobutyramide

N-(5-tert-Butyl-isoxazol-3-yl)-2-(5-chloro-indol-1-yl)-isobutyramide

2-(2-Aza-spiro[4.5]dec-2-yl)-N-(3-tert-butyl-isoxazol-5-yl)-isobutyramide

N-(3-tert-Butyl-isoxazol-5-yl)-2-methyl-2-[(tetrahydro-pyran-4-ylmethyl)-amino]-propionamide

N-(5-tert-Butyl-isoxazol-3-yl)-2-(4-chloro-phenoxy)-2-methyl-propionamide

N-(3-tert-Butyl-isoxazol-5-yl)-2-methyl-2-(tetrahydro-pyran-4-ylmethoxy)-propionamide

N-(5-tert-Butyl-isoxazol-3-yl)-2-methyl-2-[(tetrahydro-pyran-4-ylmethyl)-amino]-propionamide

N-(3-tert-Butyl-isoxazol-5-yl)-2-methyl-2-(tetrahydro-pyran-4-ylamino)-propionamide

N-(5-tert-Butyl-isoxazol-3-yl)-2-methyl-2-(tetrahydro-pyran-4-ylamino)-propionamide

2-Methyl-N-(5-phenyl-2H-1,2,4-triazol-3-yl)-2-[(tetrahydro-pyran-4-ylmethyl)-amino]-propionamide

2-Methyl-N-(5-phenyl-2H-1,2,4-triazol-3-yl)-2-(tetrahydro-pyran-4-ylamino)-propionamide

N-(3-tert-Butyl-isoxazol-5-yl)-2-methyl-2-(4-trifluoromethyl-phenylamino)-propionamide

N-(3-tert-Butyl-isoxazol-5-yl)-2-methyl-2-(5-trifluoromethyl-pyridin-2-ylamino)-propionamide

N-(5-tert-Butyl-isoxazol-3-yl)-2-methyl-2-(5-trifluoromethyl-pyridin-2-ylamino)-propionamide

N-(5-tert-Butyl-isoxazol-3-yl)-2-[(4-chloro-benzenesulfonyl)-methyl-amino]-2-methyl-propionamide

N-(5-tert-Butyl-isoxazol-3-yl)-2-[(4-fluoro-benzenesulfonyl)-methyl-amino]-2-methyl-propionamide

N-[1-(5-tert-Butyl-isoxazol-3-ylcarbamoyl)-1-methyl-ethyl]-4-chloro-N-methyl-benzamide

1,1-Dioxo-1λ6-thiomorpholine-4-carboxylic acid [1-(5-tert-butyl-isoxazol-3-ylcarbamoyl)-1-methyl-ethyl]-methyl-amide

N-(3-tert-Butyl-isoxazol-5-yl)-2-methyl-2-(tetrahydro-pyran-4-ylmethoxy)-propionamide

N-(5-tert-Butyl-isoxazol-3-yl)-2-methyl-2-(tetrahydro-pyran-4-ylmethoxy)-propionamide

N-(3-tert-Butyl-isoxazol-5-yl)-2-methyl-2-(tetrahydro-pyran-4-yloxy)-propionamide

N-(5-tert-Butyl-isoxazol-3-yl)-2-methyl-2-(tetrahydro-pyran-4-yloxy)-propionamide

2-Methyl-N-(5-phenyl-2H-1,2,4-triazol-3-yl)-2-(tetrahydro-pyran-4-ylmethoxy)-propionamide

2-Methyl-N-(5-phenyl-2H-1,2,4-triazol-3-yl)-2-(tetrahydro-pyran-4-yloxy)-propionamide and

N-(3-tert-Butyl-isoxazol-5-yl)-2-methyl-2-(5-trifluoromethyl-pyridin-2-yloxy)-propionamide

or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 or 2 .

4. A method of treating pain in an animal subject comprising administering to said animal subject a therapeutically effective dose of the compound according to claim 1 or 2 .

5. The method according to claim 4 wherein pain is chosen from acute pain, visceral pain, neuropathic pain, inflammatory and nociceptive pain, cancer pain and headache.